Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease

Mohammad El-Sayed; Magdy Elserafy; Maissa El Raziky; Wafaa Elakel; Yasmin Saad; Tarek Fayad; Mohamed Korany; Mai Mehrez; Rabab Salama; Maged Mahrous; Ayman Zaki; Mohamed Hassany; Islam Ammar; Kadry Elsaeed; Yehia Elshazly; Wahid Doss

doi:10.1016/j.ajg.2022.10.001

Citations

389

Views

Abstract not available for this publication.

Cite this Article (APA)

Mohammad, E., Magdy, E., Maissa, E. R., Wafaa, E., Yasmin, S., Tarek, F., Mohamed, K., Mai, M., Rabab, S., Maged, M., Ayman, Z., Mohamed, H., Islam, A., Kadry, E., Yehia, E., Wahid, D. (2023). Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease. Arab Journal of Gastroenterology. https://doi.org/10.1016/j.ajg.2022.10.001